- Home
- VNDA vs ADCT Comparison
VNDA vs ADCT Comparison
Compare VNDA & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- ADCT
- Stock Information
- Founded
- VNDA 2002
- ADCT 2011
- Country
- VNDA United States
- ADCT Switzerland
- Employees
- VNDA N/A
- ADCT N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- ADCT Health Care
- Exchange
- VNDA Nasdaq
- ADCT Nasdaq
- Market Cap
- VNDA 270.0M
- ADCT 224.3M
- IPO Year
- VNDA 2006
- ADCT 2020
- Fundamental
- Price
- VNDA $4.77
- ADCT $1.97
- Analyst Decision
- VNDA Strong Buy
- ADCT Strong Buy
- Analyst Count
- VNDA 2
- ADCT 5
- Target Price
- VNDA $15.50
- ADCT $8.00
- AVG Volume (30 Days)
- VNDA 704.2K
- ADCT 1.7M
- Earning Date
- VNDA 02-05-2025
- ADCT 11-07-2024
- Dividend Yield
- VNDA N/A
- ADCT N/A
- EPS Growth
- VNDA N/A
- ADCT N/A
- EPS
- VNDA N/A
- ADCT N/A
- Revenue
- VNDA $190,858,000.00
- ADCT $70,717,000.00
- Revenue This Year
- VNDA $5.60
- ADCT $6.58
- Revenue Next Year
- VNDA $42.85
- ADCT $11.78
- P/E Ratio
- VNDA N/A
- ADCT N/A
- Revenue Growth
- VNDA N/A
- ADCT N/A
- 52 Week Low
- VNDA $3.46
- ADCT $1.28
- 52 Week High
- VNDA $6.75
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- VNDA 42.69
- ADCT 43.59
- Support Level
- VNDA $4.49
- ADCT $1.90
- Resistance Level
- VNDA $4.81
- ADCT $2.21
- Average True Range (ATR)
- VNDA 0.18
- ADCT 0.42
- MACD
- VNDA -0.03
- ADCT -0.03
- Stochastic Oscillator
- VNDA 25.71
- ADCT 9.76
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.